RA Capital Management’s Tyra Biosciences TYRA Stock Holding History

RA Capital Management’s Portfolio TYRA Stock Details TYRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$467M	Hold	12,198,625	–	–	4.95%	4
2025 Q4	$321M	Hold	12,198,625	–	–	3.29%	8
2025 Q3	$171M	Hold	12,198,625	–	–	2.1%	13
2025 Q2	$117M	Buy	12,198,625 +1,561,335	+15%	+$14.8M	1.97%	15
2025 Q1	$98.9M	Hold	10,637,290	–	–	1.65%	15
2024 Q4	$148M	Buy	10,637,290 +220,681	+2%	+$4M	1.97%	13
2024 Q3	$245M	Hold	10,416,609	–	–	2.82%	7
2024 Q2	$167M	Hold	10,416,609	–	–	2.2%	13
2024 Q1	$171M	Buy	10,416,609 +3,180,155	+44%	+$52.2M	2.17%	10
2023 Q4	$100M	Hold	7,236,454	–	–	1.57%	15
2023 Q3	$99.6M	Hold	7,236,454	–	–	1.96%	11
2023 Q2	$123M	Hold	7,236,454	–	–	2.33%	10
2023 Q1	$116M	Hold	7,236,454	–	–	2.63%	11
2022 Q4	$55M	Hold	7,236,454	–	–	1.12%	27
2022 Q3	$63.6M	Hold	7,236,454	–	–	1.36%	24
2022 Q2	$51.7M	Hold	7,236,454	–	–	1.38%	23
2022 Q1	$77.4M	Hold	7,236,454	–	–	1.69%	14
2021 Q4	$102M	Hold	7,236,454	–	–	1.8%	13
2021 Q3	$127M	Buy	+7,236,454	New	+$138M	1.76%	18

Other funds holding TYRA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

APMC

Alta Partners Management Company Jackson, Wyoming $151M AUM 296.21% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RA Capital Management's TYRA Position: Q1 2026 in Review

RA Capital Management held its Tyra Biosciences (TYRA) position steady in Q1 2026 at 12,198,625 shares worth $467M. The position accounts for 4.95% of the portfolio, ranked #4.

RA Capital Management first reported a position in TYRA in Q3 2021 and has held it in 19 quarters since. 164 funds tracked by Wall St. Rank hold TYRA as of Q1 2026.

RA Capital Management held 12,198,625 shares of Tyra Biosciences worth $467M as of Q1 2026.
RA Capital Management left its Tyra Biosciences share count unchanged in Q1 2026.
Tyra Biosciences made up 4.95% of RA Capital Management's portfolio in Q1 2026, its #4 holding.
RA Capital Management first reported a position in Tyra Biosciences in Q3 2021 and has held it in 19 quarters since.
164 funds tracked by Wall St. Rank held Tyra Biosciences as of Q1 2026.

Based on RA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.